Eosinophilic airway inflammation in COPD

Shironjit Saha, Christopher E Brightling, Shironjit Saha, Christopher E Brightling

Abstract

Chronic obstructive pulmonary disease is a common condition and a major cause of mortality. COPD is characterized by irreversible airflow obstruction. The physiological abnormalities observed in COPD are due to a combination of emphysema and obliteration of the small airways in association with airway inflammation. The predominant cells involved in this inflammatory response are CD8+ lymphocytes, neutrophils, and macrophages. Although eosinophilic airway inflammation is usually considered a feature of asthma, it has been demonstrated in large and small airway tissue samples and in 20%-40% of induced sputum samples from patients with stable COPD. This airway eosinophilia is increased in exacerbations. Thus, modifying eosinophilic inflammation may be a potential therapeutic target in COPD. Eosinophilic airway inflammation is resistant to inhaled corticosteroid therapy, but does respond to systemic corticosteroid therapy, and the degree of response is related to the intensity of the eosinophilic inflammation. In COPD, targeting treatment to normalize the sputum eosinophilia reduced the number of hospital admissions. Whether controlling eosinophilic inflammation in COPD patients with an airway eosinophilia will modify disease progression and possibly alter mortality is unknown, but warrants further investigation.

Figures

Figure 1
Figure 1
Sputum eosinophil count in subjects with corticosteroid-naïve asthma and COPD. Data derived from Brightling, Monteiro, et al (2000); Green, Brightling, Woltmann, et al (2002).
Figure 2
Figure 2
Improvement in post-bronchodilator FEV1, health status (Chronic Respiratory Disease Questionnaire; CRQ), and shuttle walk distance in subjects with COPD with or without a sputum eosinophilia (>3% non-squamous cells). *p < 0.05; Δ represents change after prednisolone compared with placebo. Data derived from Brightling, Monteiro, et al (2000).

References

    1. Balbi B, Majori M, Bertacco S, et al. Inhaled corticosteroids in stable COPD patients: do they have effects on cells and molecular mediators of airway inflammation? Chest. 2000;117:1633–7.
    1. Balzano G, Stefanelli F, Iorio C, et al. Eosinophilic inflammation in stable chronic obstructive pulmonary disease. Relationship with neutrophils and airway function. Am J Respir Crit Care Med. 1999;160(5Pt1):1486–92.
    1. Barnes NC. Inhaled steroids in COPD. Lancet. 1998;351:766–7.
    1. Barnes NC, Qui Y, Pavord I, et al. Salmeterol/fluticasone proprionate: anti-inflammatory effects in COPD. Proc Am Thorac Soc. 2005;2:A543.
    1. Barnes PJ, Ito K, Adcock IM. Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. Lancet. 2004;363:731–3.
    1. Belda J, Leigh R, Parameswaran K, et al. Induced sputum cell counts in healthy adults. Am J Respir Crit Care Med. 2000;161(2Pt1):475–8.
    1. Berry MA, Hargadon B, McKenna S, et al. Observational study of the natural history of eosinophilic bronchitis. Clin Exp Allergy. 2005;35:598–601.
    1. Birring SS, Brightling CE, Bradding P, et al. Clinical, radiologic, and induced sputum features of chronic obstructive pulmonary disease in nonsmokers: a descriptive study. Am J Respir Crit Care Med. 2002;166:1078–83.
    1. Boutten A, Bonay M, Laribe S, et al. Decreased expression of interleukin 13 in human lung emphysema. Thorax. 2004;59:850–4.
    1. Bozza PT, Yu W, Penrose JF, et al. Eosinophil lipid bodies: specific, inducible intracellular sites for enhanced eicosanoid formation. J Exp Med. 1997;186:909–20.
    1. Brightling CE, McKenna S, Hargadon B, et al. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax. 2005;60:193–8.
    1. Brightling CE, Monteiro W, Ward R, et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2000;356:1480–5.
    1. Brightling CE, Ward R, Woltmann G, et al. Induced sputum inflammatory mediator concentrations in eosinophilic bronchitis and asthma. Am J Respir Crit Care Med. 2000;162(3Pt1):878–82.
    1. Brightling CE, Woltmann G, Wardlaw AJ, et al. Development of irreversible airflow obstruction in a patient with eosinophilic bronchitis without asthma. Eur Respir J. 1999;14:1228–30.
    1. Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000;320:1297–303.
    1. Burge PS, Calverley PMA, Jones PW, et al. Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Thorax. 2003;58:654–8.
    1. Chalmers GW, Macleod KJ, Thomson L, et al. Smoking and airway inflammation in patients with mild asthma. Chest. 2001;120:1917–22.
    1. Chanez P, Vignola AM, O’Shaugnessy T, et al. Corticosteroid reversibility in COPD is related to features of asthma. Am J Respir Crit Care Med. 1997;155:1529–34.
    1. Confalonieri M, Mainardi E, Della Porto R, et al. Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease. Thorax. 1998;53:583–5.
    1. Culpitt SV, Maziak W, Loukidis S, et al. Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;160:1635–9.
    1. Denburg JA. Bone marrow in atopy and asthma: hematopoietic mechanisms in allergic inflammation. Immunol Today. 1999;20:111–13.
    1. Di Stefano A, Capelli A, Lusuardi M, et al. Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med. 1998;158:1277–85.
    1. Domagala-Kulawik J, Maskey-Warzechowsksa M, Kraszewska I, et al. The cellular composition and macrophage phenotype in induced sputum in smokers and ex-smokers with COPD. Chest. 2003;123:1054–9.
    1. Douwes J, Gibson P, Pekkanen J, et al. Non-eosinophilic asthma: importance and possible mechanisms. Thorax. 2002;57:643–8.
    1. Dvorak AM, Weller PF. Ultrastructural analysis of human eosinophils. Chem Immunol. 2000;76:1–28.
    1. Edwards BS, Curry MS, Tsuji H, et al. Expression of P-selectin at low site density promotes selective attachment of eosinophils over neutrophils. J Immunol. 2000;165:404–10.
    1. Erin EM, Williams TJ, Barnes PJ, et al. Eotaxin receptor (CCR3) antagonism in asthma and allergic disease. Curr Drug Targets Inflamm Allergy. 2002;1:201–14.
    1. Fan VS, Bryson CL, Curtis JR, et al. Inhaled corticosteroids in chronic obstructive pulmonary disease and risk of death and hospitalization: time-dependent analysis. Am J Respir Crit Care Med. 2003;168:1488–94.
    1. Flood-Page PT, Menzies-Gow AN, Kay AB, et al. Eosinophil’s role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med. 2003;167:199–204.
    1. Fujimoto K, Kubo K, Yamamoto H, et al. Eosinophilic inflammation in the airway is related to glucocorticoid reversibility in patients with pulmonary emphysema. Chest. 1999;115:697–702.
    1. Gamble E, Grootendorst DC, Brightling CE, et al. Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003;168:976–82.
    1. Gibson PG, Dolovich J, Denburg J, et al. Chronic cough: eosinophilic bronchitis without asthma. Lancet. 1989;1:1346–8.
    1. Gibson PG, Woolley KL, Carty K, et al. Induced sputum eosinophil cationic protein (ECP) measurement in asthma and chronic obstructive airway disease (COAD) Clin Exp Allergy. 1998;28:1081–8.
    1. Gizycki MJ, Hattotuwa KL, Barnes N, et al. Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissue. Thorax. 2002;57:799–803.
    1. Gonzalo JA, Lloyd CM, Kremer L, et al. Eosinophil recruitment to the lung in a murine model of allergic inflammation. The role of T cells, chemokines, and adhesion receptors. J Clin Invest. 1996;98:2332–45.
    1. Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet. 2002;360:1715–21.
    1. Green RH, Brightling CE, Woltmann G, et al. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax. 2002;57:875–9.
    1. Gursel G, Turktas H, Gokcora N, et al. Comparison of sputum and serum eosinophil cationic protein (ECP) levels in nonatopic asthma and chronic obstructive pulmonary disease. J Asthma. 1997;34:313–19.
    1. Hattotuwa KL, Gizycki MJ, Ansari TW, et al. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am J Respir Crit Care Med. 2002;165:1592–6.
    1. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:2645–53.
    1. Ito K, Ito M, Elliott WM, et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med. 2005;352:1967–76.
    1. Jones PW, Willits LR, Burge PS, et al. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J. 2003;21:68–73.
    1. Keatings VM, Barnes PJ. Granulocyte activation markers in induced sputum: comparison between chronic obstructive pulmonary disease, asthma, and normal subjects. Am J Respir Crit Care Med. 1997;155:449–53.
    1. Keatings VM, Collins PD, Scott DM, et al. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med. 1996;153:530–4.
    1. Keatings VM, Evans DJ, O’Connor BJ, et al. Cellular profiles in asthmatic airways: a comparison of induced sputum, bronchial washings, and bronchoalveolar lavage fluid. Thorax. 1997;52:372–4.
    1. Keatings VM, Jatakanon A, Worsdell YM, et al. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med. 1997;155:542–8.
    1. Lacoste JY, Bousquet J, Chanez P, et al. Eosinophilic and neutrophilic inflammation in asthma, chronic bronchitis, and chronic obstructive pulmonary disease. J Allergy Clin Immunol. 1993;92:537–48.
    1. Lams BE, Sousa AR, Rees PJ, et al. Subepithelial immunopathology of the large airways in smokers with and without chronic obstructive pulmonary disease. Eur Respir J. 2000;15:512–16.
    1. Loppow D, Schleiss MB, Kanniess F, et al. In patients with chronic bronchitis a four week trial with inhaled steroids does not attenuate airway inflammation. Respir Med. 2001;95:115–21.
    1. Mahler DA, Wire P, Horstman D, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am j Respir Crit Care Med. 2002;166:1084–91.
    1. [NICE] National Institute for Clinical Excellence. Chronic obstructive pulmonary disease: national clinical guideline for management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax. 2004;59(Suppl I):1–232.
    1. O’Shaughnessy TC, Ansari TW, Barnes NC, et al. Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV1. Am J Respir Crit Care Med. 1997;155:852–7.
    1. Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med. 1999;340:1948–53.
    1. Pavord ID, Brightling CE, Woltmann G, et al. Non-eosinophilic corticosteroid unresponsive asthma. Lancet. 1999;353:2213–14.
    1. Pavord ID, Siva R, Brightling CE, et al. Prednisolone response in patients with COPD. Thorax. 2004;59:179.
    1. Pizzichini E, Pizzichini MM, Efthimiadis A, et al. Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements. Am J Respir Crit Care Med. 1996;154(2Pt1):308–17.
    1. Pizzichini E, Pizzichini MM, Gibson P, et al. Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. Am J Respir Crit Care Med. 1998;158(5Pt1):1511–17.
    1. Postma DS, Peters I, Steenhuis E, et al. Moderately severe chronic airflow obstruction. Can corticosteroids slow down obstruction? Eur Respir J. 1988;1:22–6.
    1. Qui Y, Parker D, Barnes NC, et al. The effect of salmeterol/fluticasone proprionate on eosinophils and mast cells in COPD. Proc Am Thorac Soc. 2005;2:A132.
    1. Saetta M, Baraldo S, Corbino L, et al. CD8+ve cells in the lungs of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;160:711–17.
    1. Saetta M, Di Stefano A, Maestrelli P, et al. Airway eosinophilia in chronic bronchitis during exacerbations. Am j Respir Crit Care Med. 1994;150(6Pt1):1646–52.
    1. Siva R, Green R, Brightling CE, et al. Modulation of eosinophilic inflammation in COPD [abstract]. European Respiratory Society 15th Annual Congress; Copenhagen. 17–21 Sep 2005.2005.
    1. Soriano JB, Vestbo J, Pride NB, et al. Survival in COPD patients after regular use fluticasone propionate and salmeterol in general practice. Eur Respir J. 2002;20:819–25.
    1. Stanescu D, Sanna A, Veriter C, et al. Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils. Thorax. 1996;51:267–71.
    1. Stockley RA. Biochemical and cellular mechanisms. In: Calverley PMA, Pride N, editors. Chronic obstructive pulmonary disease. 1st ed. London: Chapman and Hall; 1995. pp. 93–134.
    1. Symon FA, Lawrence MB, Williamson ML, et al. Functional and structural characterization of the eosinophil P-selectin ligand. J Immunol. 1996;157:1711–19.
    1. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 2003;21:74–81.
    1. The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease: Lung Health Study II. N Engl J Med. 2000;343:1902–9.
    1. Tomlinson JE, McMahon AD, Chaudri R, et al. Efficacy of low and high dose inhaled corticosteroid in smokers versus non-smokers with mild asthma. Thorax. 2005;60:282–7.
    1. Vestbo J, Sorensen T, Lange P, et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 1999;353:1819–23.
    1. Wardlaw AJ. Molecular basis for selective eosinophil trafficking in asthma: a multistep paradigm. J Allergy Clin Immunol. 1999;104:917–26.
    1. Woltmann G, McNulty CA, Dewson G, et al. Interleukin-13 induces PSGL-1/P-selectin-dependent adhesion of eosinophils, but not neutrophils, to human umbilical vein endothelial cells under flow. Blood. 2000;95:3146–52.
    1. Yildiz F, Kaur AC, Ilgazali A, et al. Inhaled corticosteroids may reduce neutrophilic inflammation in patients with stable chronic obstructive pulmonary disease. Respiration. 2000;67:71–6.
    1. Zhu J, Qui Y, Barnes NC, et al. The effect of salmeterol/fluticasone on pro-inflammatory gene expression in COPD. Proc Am Thorac Soc. 2005;2:A127.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever